Although the optimal choice of single-agent PARPi, as well as the possible combination strategies with other therapies, has not been determined, single-agent PARPi can now be regarded as a similar option in the therapeutic armamentarium for patients with BRCA-mutated HER2-negative metastatic or advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.